Drugs / CT-388
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04838405 | Apr 2021 → Jun 2024 | diabetes mellitus | Carmot Therapeutics, Inc. | Completed | Met primary |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-27 | Hoffmann-La Roche | [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity roche.com ↗ |
| 2026-01-26 | Genentech, Inc. | Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity gene.com ↗ |
| 2025-10-10 | Chugai Pharmaceutical | Chugai In-Licenses GLP-1/GIP Receptor Agonist CT-388 chugai-pharm.co.jp ↗ |
| 2024-05-16 | Hoffmann-La Roche | [Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity roche.com ↗ |
| 2024-05-15 | Genentech, Inc. | Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity gene.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-388 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04838405 ↗ |
| Modality | Peptide | “Synthetic Peptide” NCT04838405 ↗ |
| Route | Subcutaneous | “SC dose of CT-388” NCT04838405 ↗ |